The effect of esmolol on corrected-QT interval, corrected-QT interval dispersion changes seen during anesthesia induction in hypertensive patients taking an angiotensin-converting enzyme inhibitor  by Çeker, Zahit et al.
RS
T
c
a
a
Z
D
R
A
h
0ev Bras Anestesiol. 2015;65(1):34--40
REVISTA
BRASILEIRA  DE
ANESTESIOLOGIA Ofﬁcial  Publication  of the  Brazilian  Society  of  Anesthesiologywww.sba.com.br
CIENTIFIC ARTICLE
he  effect  of esmolol  on corrected-QT  interval,
orrected-QT interval  dispersion  changes  seen  during
nesthesia induction  in hypertensive  patients  taking
n angiotensin-converting  enzyme  inhibitor
ahit C¸eker, Suna Akın Takmaz ∗, Bülent Baltaci, Hülya Bas¸ar
epartment  of  Anesthesiolgy  and  Reanimation,  Ankara  Training  and  Research  Hospital,  Ministry  of  Health,  Ankara,  Turkey
eceived 16  January  2014;  accepted  19  March  2014
vailable  online  1  May  2014
KEYWORDS
Esmolol;
QT  interval;
QT dispersion;
ACE  inhibitor
Abstract
Background  and  objectives:  The  importance  of  minimizing  the  exaggerated  sympatho-
adrenergic  responses  and  QT  interval  and  QT  interval  dispersion  changes  that  may  develop
due  to  laryngoscopy  and  tracheal  intubation  during  anesthesia  induction  in  the  hypertensive
patients is  clear.  Esmolol  decreases  the  hemodynamic  response  to  laryngoscopy  and  intubation.
However,  the  effect  of  esmolol  in  decreasing  the  prolonged  QT  interval  and  QT  interval  disper-
sion  as  induced  by  laryngoscopy  and  intubation  is  controversial.  We  investigated  the  effect  of
esmolol  on  the  hemodynamic,  and  corrected-QT  interval  and  corrected-QT  interval  dispersion
changes  seen  during  anesthesia  induction  in  hypertensive  patients  using  angiotensin  converting
enzyme  inhibitors.
Methods:  60  ASA  I--II  patients,  with  essential  hypertension  using  angiotensin  converting  enzyme
inhibitors were  included  in  the  study.  The  esmolol  group  received  esmolol  at  a  bolus  dose  of
500  mcg/kg  followed  by  a  100  mcg/kg/min  infusion  which  continued  until  the  4th  min  after
intubation.  The  control  group  received  0.9%  saline  similar  to  the  esmolol  group.  The  mean
blood  pressure,  heart  rate  values  and  the  electrocardiogram  records  were  obtained  as  baseline
values  before  the  anesthesia,  5  min  after  esmolol  and  saline  administration,  3  min  after  the
induction  and  30  s,  2  min  and  4  min  after  intubation.
Results:  The  corrected-QT  interval  was  shorter  in  the  esmolol  group  (p  =  0.012),  the  corrected-
QT interval  dispersion  interval  was  longer  in  the  control  group  (p  =  0.034)  and  the  mean  heart
rate  was  higher  in  the  control  group  (p  =  0.022)  30  s  after  intubation.  The  risk  of  arrhythmia
frequency was  higher  in  the  control  group  in  the  4-min  period  following  intubation  (p  =  0.038).
Conclusion:  Endotracheal  intubation  was  found  to  prolong  corrected-QT  interval  and  corrected-
QT interval  dispersion,  and  increase  the  heart  rate  during  anesthesia  induction  with  propofol
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Esmolol  prevents  increase  in  QTc  and  QTcD  35
in  hypertensive  patients  using  angiotensin  converting  enzyme  inhibitors.  These  effects  were
prevented  with  esmolol  (500  mcg/kg  bolus,  followed  by  100  mcg/kg/min  infusion).  During  induc-
tion,  the  blood  pressure  tends  to  decrease  with  esmolol  where  care  is  needed.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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Efeito  de  esmolol  sobre  o  intervalo  QT  corrigido  e  alterac¸ões  da  dispersão  do
intervalo  QT  corrigido  observadas  durante  a  induc¸ão  da  anestesia  em  pacientes
hipertensos  que  receberam  um  inibidor  da  enzima  conversora  de  angiotensina
Resumo
Justiﬁcativa  e  objetivo:  É  óbvia  a  importância  de  minimizar  as  respostas  simpatoadrenérgicas
exageradas  e  o  intervalo  QT  e  a  dispersão  do  intervalo  QT  que  podem  ocorrer  por  causa  de
laringoscopia  e  intubac¸ão  traqueal  durante  a  induc¸ão  da  anestesia  em  pacientes  hipertensos.
Esmolol  diminui  a  resposta  hemodinâmica  à  laringoscopia  e  à  intubac¸ão.  Porém,  o  efeito  de
esmolol  sobre  a  reduc¸ão  do  intervalo  QT  prolongado  e  a  dispersão  do  intervalo  QT  induzida  pela
laringoscopia  e  intubac¸ão  é  controverso.  Pesquisamos  o  efeito  de  esmolol  sobre  a  hemodinâmica
e  o  intervalo  QT  corrigido  e  as  alterac¸ões  da  dispersão  do  intervalo  QT  observadas  durante  a
induc¸ão  da  anestesia  em  pacientes  hipertensos  que  receberam  inibidores  da  enzima  conversora
de  angiotensina  (IECA).
Métodos: Foram  incluídos  no  estudo  60  pacientes,  estado  físico  ASA  I-II,  com  hipertensão
arterial essencial  e  que  receberam  IECA.  O  grupo  esmolol  recebeu  uma  dose  em  bolus  de
500  mcg  kg−1,  seguida  por  infusão  contínua  de  100  mcg  kg−1 min−1 até  o  quarto  minuto  após  a
intubac¸ão.  O  grupo  controle  recebeu  soluc¸ão  salina  a  0,9%,  semelhantemente  ao  grupo  esmolol.
Os  valores  da  pressão  arterial  média  e  da  frequência  cardíaca  e  os  registros  do  eletrocardio-
grama foram  obtidos  durante  a  fase  inicial  pré-anestesia,  cinco  minutos  após  a  administrac¸ão
de esmolol  e  soluc¸ão  salina,  três  minutos  após  a  induc¸ão  e  30  segundos,  dois  minutos  e  qua-
tro minutos  após  a  intubac¸ão.
Resultados:  O  intervalo  QT  corrigido  foi  menor  no  grupo  esmolol  (p  =  0,012),  o  intervalo  de  dis-
persão do  intervalo  QT  corrigido  foi  maior  no  grupo  controle  (p  =  0,034)  e  a  frequência  cardíaca
média  foi  maior  no  grupo  controle  (p  =  0,022)  30  segundos  após  a  intubac¸ão.  O  risco  da  frequên-
cia  de  arritmia  foi  maior  no  grupo  controle  no  quarto  minuto  após  a  intubac¸ão  (p  =  0,038).
Conclusão:  Descobrimos  que  a  intubac¸ão  traqueal  prolonga  o  intervalo  e  a  dispersão  do  intervalo
QT corrigido  e  aumenta  a  frequência  cardíaca  durante  a  induc¸ão  da  anestesia  com  propofol  em
pacientes  hipertensos  que  receberam  IECA.  Esses  efeitos  foram  prevenidos  com  esmolol  (bolus
de  500  mcg  kg−1,  seguido  de  100  mcg  kg−1 min−1 de  infusão).  Durante  a  induc¸ão,  a  pressão  tende
a  diminuir  com  esmolol.  Portanto,  cuidados  são  necessários.
©  2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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A  prolonged  QT  interval  and  corrected-QT  interval  (QTc)
combined with  QT  interval  dispersion  (QTD)  and  corrected-
QTD (QTcD)  are  known  to  increase  the  incidence  of  fatal
arrhythmias such  as  polymorphic  ventricular  arrhythmia  or
ventricular ﬁbrillation  and  cause  sudden  deaths  by  caus-
ing cardiac  irritability.1,2 An  increase  in  sympathetic  activity
and plasma  catecholamine  concentrations  is  known  to  cause
prolongation of  the  QT  interval  and  QT  dispersion.  Laryn-
goscopy and  tracheal  intubation  have  been  shown  to  cause
hyperdynamic responses  such  as  hypertension,  tachycar-
dia, arrhythmia  and  prolongation  of  the  QT  interval.3,4
Although  the  observed  hemodynamic  responses  are  tempo-
rary, they  may  cause  serious  complications  such  as  cerebral
a
h
hemorrhage,  arrhythmia,  myocardial  ischemia  or  even
nfarction in  the  presence  of  accompanying  cerebrovascular
isease, coronary  artery  disease  or  hypertension.5,6
Essential  hypertension  is  the  most  common  accompany-
ng disorder  in  patients  admitted  for  surgery.7 The  disturbed
ardiovascular homeostasis  in  hypertensive  patients  has
een shown  to  cause  a  sympatho-vagal  imbalance  char-
cterized by  decreased  vagal  modulation  and  increased
ympathetic activity.8 The  response  to  laryngoscopy  is
igniﬁcantly different  in  hypertensive  patients  compared
o normotensive  patients.  The  blood  pressure  changes
hat develop  immediately  following  anesthesia  induction
re much  larger  in  hypertensive  patients.  These  patients
ave marked  hypotension  with  induction  and  marked
ypertension with  laryngoscopy  and  intubation.9 A  blood
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ressure  ﬂuctuation  of  more  than  20%  in  hypertensive
atients has  been  shown  to  be  associated  with  perioper-
tive complications.  The  most  common  cause  of  sudden
ardiac death  in  hypertensive  cases  unaccompanied  by
oronary artery  disease  has  been  reported  to  be  ventri-
ular arrhythmias10 and  QTD  prolongation  in  hypertensive
atients has  been  found  to  be  associated  with  sudden
eath.11 The  importance  of  minimizing  the  exaggerated
ympatho-adrenergic  responses  and  QT  interval  and  QTD
hanges during  anesthesia  induction  in  the  hypertensive
atient group  is  therefore  clear.  To  prevent  such  detri-
ental events  different  classes  of  drugs  have  been  used.
smolol is  a  cardioselective  beta-adrenergic  blocking  agent
ith a  rapid  onset  of  action  and  quite  short  elimina-
ion half-time.  It  is  known  to  decrease  the  hemodynamic
esponse to  laryngoscopy  and  intubation.12,13 However,
he results  of  the  limited  number  of  studies  where  the
ffect of  esmolol  in  decreasing  the  prolonged  QT  interval
nd QTD  as  induced  by  laryngoscopy  and  intubation  are
ontroversial.
There is  a  consensus  on  continuing  antihypertensive
edication  until  the  morning  of  the  day  of  surgery  at
resent. However,  the  use  of  angiotensin  converting  enzyme
nhibitors (ACEIs)  is  debated  due  to  the  potential  of  devel-
ping hypotension  resistant  to  vasopressors.  Some  authors
eport the  need  to  continue,14 while  others  believe  they
hould be  discontinued.15 We  did  not  ﬁnd  any  studies  on
he effect  of  esmolol  on  the  hemodynamic  and  QT  inter-
al and  QTD  changes  seen  during  anesthesia  induction  in
ypertensive patients  taking  a  ACEIs.
The  aim  of  this  study  was  to  investigate  the  effect  of
smolol on  the  hemodynamic,  QTc  and  QTcD  changes  during
nesthesia induction  seen  in  hypertensive  patients  taking  a
CEIs.
ethods
 total  of  60  patients  aged  20--65  years  and  taking  a ACEIs
ith regulated  essential  hypertension,  who  were  about  to
ndergo elective  surgery  were  included  in  this  prospective,
andomized, double-blind  study  after  obtaining  ethic  com-
ittee approval  and  written  patient  consent.  Patients  with
nstable angina,  severe  conduction  disorder  or  arrhythmia,
hronic obstructive  pulmonary  disease,  cardiac  failure  and
ardiac valve  disease,  those  using  drugs  known  to  prolong
he QT  interval  (such  as  tricyclic  antidepressants,  quini-
ine, disopyramid,  sotolol,  Ca  channel  blockers),  patients
ith electrolyte  disorders  or  abnormal  blood  coagulation
roﬁles, patients  known  to  be  hypersensitive  to  the  med-
cation to  be  used  and  pregnant  women  were  excluded  from
he study.  Patients  to  whom  the  intubation  could  be  difﬁ-
ult and  those  who  were  intubated  after  several  attempts
ere not  included  in  the  study.  Information  was  provided
n the  method  to  be  used  and  verbal  and  written  consent
ere obtained  from  the  patients  on  the  preoperative  visit
he day  before  surgery.  Antihypertensive  treatment  was  con-
inued until  the  morning  of  surgery  but  no  premedication
as administered.
Following vascular  access  with  a  20  G  intracath  in  the
perating room,  the  patients  were  monitored  for  pulse
ximetry (Draeger  inﬁnity  delta  monitor,  USA),  non-invasive
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lood  pressure  (Draeger  inﬁnity  delta  monitor,  USA)  and  a
2-lead electrocardiogram  (ECG)  device  (Trismed,  Cardipia
00). The  initial  heart  rate  (HR),  mean  blood  pressure  (MBP)
alues and  12-lead  ECG  were  recorded.  The  patients  were
rospectively randomized  by  computer  to  one  of  the  esmolol
nd control  groups.  Esmolol  (Breviblock,  Eczacıbas¸ı-Baxter
o) was  administered  as  a  100  mcg/kg/min  infusion  follow-
ng a  500  mcg/kg  bolus  dose  (in  5  mL  of  volume,  within  30  s)
n the  esmolol  group.  The  esmolol  infusion  was  continued  up
o 4  min  after  the  intubation.  A  bolus  and  infusion  admin-
stration similar  to  the  esmolol  group  was  performed  with
.9% saline  in  the  control  group.  Anesthesia  was  induced
ith 2  mg/kg  propofol  and  1  mcg/kg  fentanyl  5  min  after
smolol or  saline  induction  in  both  groups.  Patients  were
ntubated within  3  min  of  vecuronium  (1  mg/kg)  adminis-
ration by  an  experienced  anesthetist  and  the  procedure
asted 20  s  on  average.  Patients  whose  MBP  decreased  to
elow 55  mmHg  and  the  HR  to  below  50/min  were  admin-
stered 5  mg  ephedrine  and  0.5  mg  atropine.  The  esmolol
nfusion was  discontinued  if  there  was  no  response  to
edication. The  MBP,  HRs  and  ECG  (at  a  sweep  rate  of
0 mm  s)  of  the  patients  were  recorded  as  a  baseline  value
efore the  anesthesia  (T0),  5  min  after  esmolol  or  saline
dministration (T1),  3  min  after  induction  medication  (T2),
0 s  after  the  intubation  (T3),  2  min  after  the  intubation
T4), and  4  min  after  the  intubation  (T5)  for  a  total  of
 times.
The study  drugs  were  prepared  by  an  anesthetist  who
as not  included  in  the  study  and  did  not  know  the  patient
roups. The  records  were  kept  by  another  anesthetist  who
gain did  not  know  the  patient  groups.  ECG  records  were
valuated by  a  cardiologist  who  did  not  know  the  patient
roups. The  distance  from  the  start  of  the  QRS  complex
o the  end  of  the  T  wave  was  accepted  as  the  QT  inter-
al. When  the  T  wave  was  bi-notched,  the  end  of  the  T
ave was  accepted  as  the  point  where  the  ﬁrst  wave’s
xtension reached  the  isoelectric  line  when  the  second
otch was  smaller  than  50%  of  the  ﬁrst  notch  and  as  the
oint where  the  second  wave  reached  the  isoelectric  line
f it  was  larger  than  50%  of  the  ﬁrst  notch.  Three  QT  dis-
ances were  measured  for  each  derivation  and  averaged.
T intervals  corrected  for  HR  (QTc)  were  calculated  for
ll derivations  using  Bazett’s  formula  (QTc  =  QT(ms)/RR(sn)1/2).
he average  of  the  QTc  values  of  three  consecutive  heart-
eats at  each  derivation  was  accepted  as  the  QTc  interval
f that  derivation.  QTD  was  calculated  as  the  differ-
nce between  the  longest  QT  distance  and  the  shortest
T distance  at  each  interval  while  QTcD  was  calculated
s the  difference  between  the  longest  and  shortest  QTc
alues.
Statistical analysis  was  performed  with  the  ‘‘SPSS  16.0
or Windows  software’’  (SPSS,  Inc.,  Chicago,  IL,  USA).
ssuming an  alpha  level  of  0.05  and  a  power  of  0.80,  a  mini-
um of  21  patient  in  each  group  were  required  to  detect
 mean  difference  of  20  ms  and  22  ms  of  standard  devi-
tion for  the  QTc  interval  between  the  two  groups.  The
ifferences between  the  groups  were  evaluated  with  the
‘independent samples  t-test’’  or  ‘‘chi-square’’  tests.  The
BP, HR,  QTc  interval  and  QTcD  changes  in  each  group  were
valuated with  the  analysis  of  variance  test  (with  the  Bon-
erroni correction).  A  p  value  less  than  0.05  was  accepted
s statistically  signiﬁcant.
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Table  1  Demographic  and  clinical  data  (mean  ±  SD).
Esmolol  (n  =  30)  Control  (n  =  30)  p-value
Age  (years)  57.0  ±  6.9  57.9  ±  6.8  0.589
Gender  (female/male)  7/23  9/21  0.559
ASA  (I/II)  16/14  21/9  0.184
Height  (cm)  159.8  ±  7.6  162.2  ±  7.7  0.120
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Results
There  was  no  difference  between  the  groups  regarding
demographic data  (Table  1).  The  mean  basal  blood  pressure,
HR, QTc  interval  and  QTcD  values  were  similar  in  the  two
groups.
The MBP  was  lower  in  the  esmolol  group  than  the  control
group at  the  T1  (84.1  ±  17.4  vs.  98.2  ±  14.7),  T2  (62.8  ±  8.5
vs. 87.7  ±  11.5)  and  T3  (75.4  ±  6.8  vs.  91.3  ±  21.2)  mea-
surement times  (Fig.  1).  There  was  a  marked  decrease  in
MBP levels  compared  to  baseline  at  all  measurement  times
after the  induction  drugs  were  administered  (T2)  in  the  con-
trol group  (T2:  p  =  0.001;  T3:  p  =  0.020;  T4:  p  =  0.025;  T5:
p =  0.001)  and  at  all  measurement  times  after  esmolol  was
administered (T1)  in  the  esmolol  group  (T1:  p  =  0.001;  T2:
p =  0.001;  T3:  p  =  0.001;  T4:  p  =  0.002;  T5:  p  =  0.001).  The
esmolol group,  in  contrast  to  the  control  group,  showed  a
markedly larger  decrease  in  MBP  following  propofol  induc-
tion (T2)  (Fig.  1)  (p  =  0.001).
Comparison  of  mean  HR  values  showed  a  signiﬁcant  dif-
ference between  the  groups  in  the  measured  values  30  s
after intubation  (T3).  The  mean  HR  was  markedly  higher
30 s  after  intubation  (T3)  in  the  control  group  (84.2  ±  15.6
vs. 93.2  ±  13.9,  p  =  0.022).  The  HR  in  the  esmolol  group  was
lower than  the  baseline  value  at  all  measurement  times
except T3  (T1:  p  =  0.007;  T2:  p  =  0.001;  T4:  p  =  0.015;  T5:
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Figure  1  Mean  ‘‘blood  pressure’’  values  in  the  esmolol  and
control groups.  T0,  basal  value;  T1,  5  min  post-esmolol  admin-
istration; T2,  2  min  post-induction  drugs  administration;  T3,
30 s  post-intubation;  T4,  2  min  post-intubation;  T5,  4  min  post-
intubation. *p  =  0.001,  when  the  two  groups  are  compared;
#p  =  0.001,  when  compared  with  the  baseline; ¥p  =  0.002,  when
compared with  the  baseline; +p  =  0.001,  when  compared  with
the baseline; ++p  =  0.020,  when  compared  with  the  baseline;
+++p  =  0.025,  when  compared  with  the  baseline.
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 =  0.001)  while  it  was  similar  to  the  baseline  value  30  s  after
ntubation. The  HR  values  in  the  control  group  were  lower
han baseline  at  the  T2  measurement  time  (p  =  0.003)  and
igher than  the  baseline  at  T3  (Fig.  2)  (p  =  0.001).
The mean  basal  QTc  values  of  the  patients  were  simi-
ar in  the  2  groups.  The  baseline  QTc  values  were  higher
han 440  ms  in  12  (40%)  patients  from  the  esmolol  group
nd 10  (33%)  patients  from  the  control  group  with  no  dif-
erence between  the  groups  (p  >  0.05).  The  QTc  interval  was
arkedly shorter  in  the  esmolol  group  than  the  control  group
0 s  after  intubation  (T3)  (439.7  ±  27.8  vs.  458.7  ±  29.3
 =  0.012).  The  QTc  interval  duration  shortened  slightly  after
smolol administration  but  this  was  not  statistically  signif-
cant. The  QTc  interval  was  similar  to  the  baseline  at  all
easurement times  (p  =  0.618).  The  QTc  interval  values  30  s
T3) and  2  min  (T4)  after  intubation  in  the  control  group
ere longer  than  both  baseline  values  (p  =  0.001,  p  =  0.001)
nd the  time  at  T1  (p  =  0.001,  p  =  0.003)  (Fig.  3).
The  mean  baseline  QTcD  values  of  the  patients  were  simi-
ar in  the  two  groups.  The  QTcD  interval  was  markedly  longer
n the  control  group  than  the  esmolol  group  30  s  after  intuba-
ion (T3)  (p  =  0.034).  The  QTcD  interval  values  in  the  esmolol
roup did  not  show  a  statistically  signiﬁcant  change  at  any
easurement time  (p  =  0.061).  The  QTcD  values  in  the  con-
rol group  were  longer  than  the  baseline  after  the  induction
rugs (T2)  and  2  min  after  intubation  (T3)  and  longer  than
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et al.24 have  recently  published  an  article  where  they  inves-p  =  0.003,  when  compared  with  the  baseline; p  =  0.001,  when
ompared with  the  baseline; ¥p  =  0.006,  when  compared  with
he baseline; t p  =  0.036,  when  compared  with  the  baseline.
oth  the  baseline  and  T1  (post-esmolol)  levels  30  s  after
ntubation (T3)  (Fig.  4).
There  was  no  need  to  use  atropine  in  the  patients  while
phedrine was  required  in  3  patients  in  the  esmolol  group.
he esmolol  infusion  did  not  need  to  be  discontinued  in
ny patient.  The  incidence  of  arrhythmia  development  was
igher in  the  4  min  after  intubation  in  the  control  group
p = 0.038).  Unifocal  ventricular  extrasystoles  developed  in
 patients  from  the  esmolol  group  while  multifocal  ven-
ricular extrasystoles  developed  in  4  patients,  ventricular
igeminy in  1  patient,  and  unifocal  ventricular  extrasystoles
n 3  patients  from  the  control  group.
iscussionn  this  study  we  investigated  the  effect  of  esmolol  on
he induction  hemodynamics,  and  QTc  interval  and  QTcD
t
i
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hanges  in  a  hypertensive  patient  group  taking  ACEIs.
he QTc  and  QTcD  prolongation  following  intubation  was
ept under  control  with  500  mcg/kg  bolus  esmolol  fol-
owed by  a  100  mcg/kg/min  infusion.  Esmolol  also  stopped
he increased  HR  following  intubation.  However,  esmolol
ed to  a  marked  decrease  in  blood  pressure  during
nduction.
As far  as  we  know,  our  study  is  the  ﬁrst  to  investigate
he effect  of  esmolol  on  hemodynamic  responses  induced
y laryngoscopy  and  tracheal  intubation  and  also  on  the
T interval  and  QTD  in  a  hypertensive  patient  group  taking
CEIs. Although  there  have  been  many  studies  on  the  sup-
ression of  the  intubation-related  hemodynamic  responses
ith esmolol,  there  is  no  consensus  on  the  optimum  time  and
oute of  administration.  A  large  meta-analysis  by  Figueredo
nd Garcia-Fuentes13 on  the  effectiveness  of  esmolol  for  the
uppression of  intubation-related  hemodynamic  responses  in
900 patients  evaluated  11  different  regimes  and  doses  of
smolol in  a  systematic  manner.  The  result  was  that  esmolol
as effective  in  suppressing  intubation-related  hemody-
amic responses  but  it  carried  a  dose-dependent  risk  of
ypotension during  anesthesia  induction.  The  most  effec-
ive dose  with  a lower  incidence  and  severity  of  side  effects
as a 500  mcg/kg  bolus  dose  followed  by  a  continuous  infu-
ion of  200  or  300  mcg/kg/min.  We  used  a 500  mcg/kg  bolus
ose of  esmolol  followed  by  a  100  mcg/kg/min  continuous
nfusion. The  infusion  dose  was  halved  for  two  reasons.
he ﬁrst  was  the  high  rate  of  hypotension  in  our  pilot
tudy with  infusion  doses  of  200  mcg/kg/min.  The  second
eason was  the  use  of  propofol  as  the  induction  agent.
lthough there  are  studies  showing  that  propofol  prolongs
he QT  interval,16,17 it  is  generally  accepted  that  propofol
as no  or  a  little  effect  on  the  QT  interval.18,19 We  there-
ore preferred  the  use  of  propofol  for  induction  instead  of
olatile agents  or  thiopental  that  are  known  to  prolong  the
T interval.  However,  propofol  is  also  known  to  be  able
o decrease  blood  pressure20,21 and  cause  bradycardia22 by
ecreasing systemic  vascular  resistance.  Korpinen  et  al.23
ave  reported  that  a  propofol--esmolol  combination  causes
emodynamic depression  in  their  study  where  they  inves-
igated the  electrocardiographic  and  hemodynamic  effects
f esmolol  combined  with  methohexital  and  propofol  dur-
ng anesthesia  induction.  Taking  into  account  that  our  study
ould be  performed  on  the  hypertensive  patient  group
here hemodynamic  ﬂuctuations  are  more  prominent,  we
ecreased the  infusion  dose  so  as  not  to  cause  more  car-
iovascular depression  during  esmolol  usage.  The  esmolol
oses we  used  prevented  the  increase  in  HR  following  intu-
ation but  preserved  the  beginning  HR  values  in  the  control
roup. However,  the  decrease  observed  in  MBP  during  induc-
ion is  much  higher  than  the  decrease  in  the  control  group
nd noteworthy.  We  believe  that  the  vasodilation-causing
ffect of  both  propofol  and  the  ACE  inhibitor  in  the  hyper-
ensive patient  group  becomes  potentiated  with  esmolol  in
he hypertensive  patient  group.  However,  controlled  stud-
es are  needed  to  verify  this  opinion.  It  may  be  useful  to
ecrease propofol  dose  to  avoid  deep  hypotension  during
nduction in  hypertensive  patients  taking  ACEIs.  Weisenbergigated the  hemodynamic  changes  caused  by  anesthesia
nduction with  propofol  at  4  different  doses  in  patients  using
 ACEIs.  They  decided  that  a  dose  of  1.3  mg/kg  decreased
w
p
a
p
c
o
o
h
d
o
a
s
i
a
w
b
t
d
C
T
R
1
1
1Esmolol  prevents  increase  in  QTc  and  QTcD  
hemodynamic  instability.  However  in  this  study  bispectral
index monitorization  was  not  used  and  optimal  hemo-
dynamic control  was  assumed  synonymous  with  optimal
anesthesia includes  analgesia  and  amnesia.  More  studies  are
needed to  determine  the  optimum  dose  during  the  use  of
esmolol with  propofol  induction  in  hypertensive  patients
taking ACEIs.
It is  known  that  there  is  a  close  relationship  between
essential hypertension  and  the  autonomous  nervous  system
and that  the  frequency  of  cardiac  arrhythmias  increases
in patients  with  disturbed  QT  dynamicity.25 Increased  QTD
in hypertensive  patients  has  been  found  to  be  associated
with sudden  death11 and  various  antihypertensive  drugs
have been  shown  to  decrease  the  incidence  of  QTD  and
arrhythmia.26,27 Taking  into  account  that  laryngoscopy  and
sympathetic activation  also  prolong  the  QT  interval  and
QTD, it  may  be  clinically  signiﬁcant  to  use  methods  that
decrease the  QTD  in  hypertensive  patients  to  prevent  the
sympatho-adrenergic responses  induced  by  laryngoscopy
and tracheal  intubation.  Beta-blockers  known  to  decrease
the cardiovascular  responses  to  sympathetic  stimuli  may
decrease the  development  of  arrhythmia  in  this  aspect.
Various results  have  been  reported  regarding  the  effect  of
esmolol on  the  QT  interval  induced  by  laryngoscopy  and
intubation.12,23,28--31 Korpinen  et  al.30 have  reported  that
esmolol combined  with  propofol  and  alfentanil  induction
in otolaryngology  surgery  shortens  the  QTc  interval.  The
same investigator  also  reported  in  two  separate  studies  that
esmolol shortens  the  QTc  interval  prolongation  seen  follow-
ing intravenous  anesthesic  usage  but  does  not  shorten  the
prolongation seen  following  intubation.28,29 Another  study
by the  same  investigator  combining  esmolol  with  metohex-
ital or  propofol  induction  has  reported  results  similar  to
these two  studies.23 However,  it  is  noteworthy  that  some  of
these studies  used  succinyl  choline,12,23,29 while  some  used
thiopental,29,30 and  some  anticholinergic  premedication.12,23
These  agents  are  known  to  prolong  the  QT  interval.  Erdil
et al.31 have  published  a  study  where  they  investigated  the
effect of  esmolol  on  the  QTc  interval  changes  seen  during
anesthesia induction  in  coronary  artery  disease  patients.
This study  combined  etomidate,  fentanyl  and  vecuronium
induction with  esmolol  and  reported  that  esmolol  kept  the
hemodynamic responses  to  intubation  and  the  QTc  inter-
val prolongation  following  intubation  under  control.  Esmolol
was used  at  a  bolus  dose  of  1000  mcg/kg  followed  by  an
infusion of  250  mcg/kg/min  and  no  cardiovascular  depres-
sion developed  in  the  patients  despite  this  relatively  high
dose. The  investigators  felt  this  was  due  to  the  use  of  agents
with minimal  cardiovascular  effects  during  induction.  In  our
study we  found  that  the  prolonged  QTc  and  QTcD  values
that started  with  anesthesia  induction  and  peaked  with  intu-
bation in  the  control  group  were  prevented  with  esmolol.
Besides, arrhythmia  occurrence  frequency  after  entubation
was also  decreased  with  esmolol.  Recently,  Kaneko  et  al.32
investigated  the  effect  of  landiolol,  an  ultra-short  acting  1
adrenoceptor  antagonist,  on  QT  interval  and  QR  dispersion.
Similar to  our  results,  they  found  that  landiolol  prevents
increase in  QT,  QTc,  QTD,  and  QTcD  during  and  after  tracheal
intubation.
We observed  that  the  basal  QTc  values  of  our  patients
were relatively  high  (439.4  ±  29.2  and  428.1  ±  25.4).  These
high values  may  be  due  to  our  patients  being  hypertensive
139
ith  high  sympatho-adrenal  tonus.  In  addition,  the  lack  of
remedication may  also  have  contributed  to  the  sympatho-
drenal tonus  increase  by  causing  anxiety.
A  limitation  of  our  study  is  that  we  did  not  compare
atients who  continued  taking  ACEIs  with  those  who  dis-
ontinued. As  we  remarked  before,  there  is  no  consensus
n whether  ACEIs  should  be  continued  until  the  morning
f surgery  due  to  the  potential  for  the  development  of
ypotension resistant  to  vasopressors.  Therefore  we  cannot
eﬁnitively recommend  whether  ACEIs  should  be  continued
r discontinued  especially  if  esmolol  infusion  is  used  during
nesthesia induction.  However  our  results  suggest  that  ACEIs
hould be  continued.
In  conclusion,  endotracheal  intubation  during  anesthesia
nduction with  propofol  was  found  to  prolong  QTc  and  QTcD
nd increase  the  HR  in  hypertensive  patients  using  ACEIs
hile esmolol  infusion  at  a  bolus  of  500  mcg/kg  followed
y 100  mcg/kg/min  infusion  prevented  these  responses.  Fur-
hermore it  was  also  found  that  the  blood  pressure  tends  to
ecrease with  esmolol  during  induction  and  care  is  needed.
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